Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate

From Startup Magenta Therapeutics

Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-presents-new-preclinical-data-mgta-145-stem

A single dose of MGTA-145 mobilized large numbers of hematopoietic
stem cells in hours that engrafted robustly in primates
MGTA-145-mobilized cells blocked graft-vs.-host disease (GvHD) in
preclinical models
MGTA-145 to enter the clinic in the first half of 2019
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 1, 2018–
Magenta
Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company
developing novel medicines to bring the curative power of bone marrow
transplant to more patients, today announced that the Company
highlighted new preclinical research on its MGTA-145 product candidate
for stem cell mobilization in an oral presentation at the 60th annual
meeting of the American Society of Hematology (ASH). MGTA-145 is being
developed as a first-line agent to enable single-day mobilization of
high numbers of hematopoietic stem cells for bone marrow transplant.

“Seventy percent of the bone marrow transplants performed in the US and
Europe each year use mobilized peripheral blood as a source of stem
cells, but current standards of care require four to six days to
mobilize an adequate number of stem cells. This is a notable burden on
patients, donors and healthcare resources, and the standard treatment
may be contraindicated or not tolerated in some patients who need
transplant,” said John Davis, M.D., M.P.H, chief medical officer,
Magenta Therapeutics. “Data at ASH this year show that MGTA-145, used in
combination with plerixafor, rapidly mobilizes robust numbers of stem
cells that successfully engrafted in non-human primates, and the cells
mobilized by the combination also blocked GvHD in a preclinical model.
Based on the body of preclinical data we have seen with MGTA-145, we
will be moving this program into the clinic in the first half of 2019 as
a promising investigational first-line therapy for stem cell
mobilization.”

MGTA-145 in Combination with Plerixafor Rapidly Mobilizes High
Numbers of Hematopoietic Stem Cells and Graft-Versus-Host
Disease-Inhibiting Myeloid-Derived Suppressor Cells in Non-Human
Primates, Abstract #116

Key results, presented by Patrick Falahee, Ph.D., Magenta Therapeutics:

MGTA-145 works synergistically with plerixafor, another agent for stem
cell mobilization, to rapidly mobilize large numbers of stem cells.

A single injection of MGTA-145 plus plerixafor mobilized sufficient
stem cells for transplant within five hours in non-human primates.

A single injection of MGTA-145 plus plerixafor mobilized 2 to 3 times
the number of stem cells in four hours compared to the number
mobilized over five days with standard of care agent G-CSF in
non-human primates.

When the cells mobilized with MGTA-145 plus plerixafor were
transplanted into a non-human primate model, they rapidly engrafted.

MGTA-145 plus plerixafor led to a 3-fold increase in immunosuppressive
monocytes mobilized over G-CSF – and the mobilized cells blocked GvHD,
a significant challenge in allogeneic bone marrow transplant.

About Magenta TherapeuticsHeadquartered in Cambridge,
Mass., Magenta Therapeutics is a clinical-stage biotechnology company
developing novel medicines for patients with autoimmune diseases, blood
cancers and genetic diseases. By creating a platform focused on critical
areas of unmet need, Magenta Therapeutics is pioneering an integrated
approach to allow more patients to receive one-time, curative therapies
by making the process more effective, safer and easier.

Forward-Looking StatementThis press release may contain
forward-looking statements, including express or implied statements
regarding Magenta’s future expectations, plans and prospects, including
projections regarding future revenues and financing performance, our
long-term growth, the anticipated timing of our clinical trials and
regulatory filings, the development of our product candidates and
advancement of our preclinical programs, as well as other statements
containing the words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” might,” “plan,” “potential,”
“project,” “should,” target,” “will” or “would” and similar expressions
that constitute forward-looking statements under the Private Securities
Litigation Reform Act of 1995. Although Magenta’s forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Magenta. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Magenta’s
programs and operations are described in additional detail in its
registration statement on Form S-1, its Quarterly Report on Form 10-Q
and its other filings made with the Securities and Exchange Commission
from time to time. Any forward-looking statement made in this press
release speaks only as of the date on which it is made. Magenta
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181201005009/en/
Source: Magenta Therapeutics

Magenta Therapeutics:Manisha Pai, Vice President,
Communications & Investor Relations617-510-9193mpai@magentatx.com

Please visit their site for more information: Magenta Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-12-01 19:57:51